Clinical Trials · NCT00635492
CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 2,515
- Start date
- Jan 2008
- Locations
- 96 sites, 5 countries
- Primary endpoint
- Estimates of Probability to Remain on Initial Injectable Treatment at 12 and 24 Months.